Dow Today: Pfizer (PFE) Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 2.0 points at 16,578 as of Thursday, May 1, 2014, 12:36 p.m. ET. During this time, 151.7 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 410.2 million. The NYSE advances/declines ratio sits at 1,778 issues advancing vs. 1,187 declining with 180 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with an 11-cent decline (-0.3%) bringing the stock to $31.17. This single loss is lowering the Dow Jones Industrial Average by 0.83 points or roughly accounting for 41.5% of the Dow's overall loss. Volume for Pfizer currently sits at 24.1 million shares traded vs. an average daily trading volume of 29 million shares.

Pfizer has a market cap of $203.06 billion and is part of the health care sector and drugs industry. Shares are up 2.1% year-to-date as of Wednesday's close. The stock's dividend yield sits at 3.3%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. The company has a P/E ratio of 19.4, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux